3 results
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
Approved WMOWill not start
Primary Objective: To study feasibility of a novel Splendor-X SMART system platform for hair removal treatment for all skin types. Secondary Objectives: To study efficacy and safety of the Splendor-X SMART system for hair removal treatment for all…
Approved WMORecruiting
Primary objective:To evaluate the efficacy of cobolimab + dostarlimab + docetaxel relative to docetaxel alone in participants with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy andChemotherapy.To evaluate the efficacy of…